235 related articles for article (PubMed ID: 18991753)
21. Current advances in drug discovery for Chagas disease.
Scarim CB; Jornada DH; Chelucci RC; de Almeida L; Dos Santos JL; Chung MC
Eur J Med Chem; 2018 Jul; 155():824-838. PubMed ID: 30033393
[TBL] [Abstract][Full Text] [Related]
22. Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery.
MacLean LM; Thomas J; Lewis MD; Cotillo I; Gray DW; De Rycker M
PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006612. PubMed ID: 30001347
[TBL] [Abstract][Full Text] [Related]
23. Current drug therapy and pharmaceutical challenges for Chagas disease.
Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
Filardi LS; Brener Z
Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
[TBL] [Abstract][Full Text] [Related]
25. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.
Guedes PM; Urbina JA; de Lana M; Afonso LC; Veloso VM; Tafuri WL; Machado-Coelho GL; Chiari E; Bahia MT
Antimicrob Agents Chemother; 2004 Nov; 48(11):4286-92. PubMed ID: 15504854
[TBL] [Abstract][Full Text] [Related]
26. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
[TBL] [Abstract][Full Text] [Related]
27. Proteomic and bioinformatic analysis of Trypanosoma cruzi chemotherapy and potential drug targets: new pieces for an old puzzle.
Sadok Menna-Barreto RF; Belloze KT; Perales J; Silva FP
Curr Drug Targets; 2014 Mar; 15(3):255-71. PubMed ID: 24041335
[TBL] [Abstract][Full Text] [Related]
28. Trypanocidal activity of 4 isopropyl salicylaldehyde and 4-isopropyl salicylic acid on Trypanosoma cruzi.
Nogueda-Torres B; Rodríguez-Paez L; Ramírez IB; Ramírez CW
Rev Latinoam Microbiol; 2001; 43(1):1-6. PubMed ID: 17061565
[TBL] [Abstract][Full Text] [Related]
29. New drugs for neglected infectious diseases: Chagas' disease.
Machado FS; Tanowitz HB; Teixeira MM
Br J Pharmacol; 2010 May; 160(2):258-9. PubMed ID: 20423339
[TBL] [Abstract][Full Text] [Related]
30. Cure of short- and long-term experimental Chagas' disease using D0870.
Urbina JA; Payares G; Molina J; Sanoja C; Liendo A; Lazardi K; Piras MM; Piras R; Perez N; Wincker P; Ryley JF
Science; 1996 Aug; 273(5277):969-71. PubMed ID: 8688084
[TBL] [Abstract][Full Text] [Related]
31. A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease.
Araújo MS; Martins-Filho OA; Pereira ME; Brener Z
J Antimicrob Chemother; 2000 Jun; 45(6):819-24. PubMed ID: 10837436
[TBL] [Abstract][Full Text] [Related]
32. Approaches for the development of new anti-Trypanosoma cruzi agents.
Moreira DR; Leite AC; dos Santos RR; Soares MB
Curr Drug Targets; 2009 Mar; 10(3):212-31. PubMed ID: 19275558
[TBL] [Abstract][Full Text] [Related]
33. A flow cytometer-based method to simultaneously assess activity and selectivity of compounds against the intracellular forms of Trypanosoma cruzi.
Miranda CG; Solana ME; Curto MLA; Lammel EM; Schijman AG; Alba Soto CD
Acta Trop; 2015 Dec; 152():8-16. PubMed ID: 26272680
[TBL] [Abstract][Full Text] [Related]
34. Insights into Chagas treatment based on the potential of bacteriocin AS-48.
Martín-Escolano R; Cebrián R; Martín-Escolano J; Rosales MJ; Maqueda M; Sánchez-Moreno M; Marín C
Int J Parasitol Drugs Drug Resist; 2019 Aug; 10():1-8. PubMed ID: 30953804
[TBL] [Abstract][Full Text] [Related]
35. Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies.
Papadopoulou MV; Bloomer WD; Rosenzweig HS; Ashworth R; Wilkinson SR; Kaiser M; Andriani G; Rodriguez A
Future Med Chem; 2013 Oct; 5(15):1763-76. PubMed ID: 24144412
[TBL] [Abstract][Full Text] [Related]
36. A decade of targets and patented drugs for chemotherapy of Chagas disease.
Duschak VG
Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):216-59. PubMed ID: 21824073
[TBL] [Abstract][Full Text] [Related]
37. Biological factors that impinge on Chagas disease drug development.
Francisco AF; Jayawardhana S; Lewis MD; Taylor MC; Kelly JM
Parasitology; 2017 Dec; 144(14):1871-1880. PubMed ID: 28831944
[TBL] [Abstract][Full Text] [Related]
38. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
[TBL] [Abstract][Full Text] [Related]
39. Trypanosoma cruzi: chemotherapeutic effects of clomipramine in mice infected with an isolate obtained from an endemic area.
Rivarola HW; Bustamante JM; Lo Presti S; Fernández AR; Enders JE; Gea S; Fretes R; Paglini-Oliva P
Exp Parasitol; 2005 Oct; 111(2):80-6. PubMed ID: 16085036
[TBL] [Abstract][Full Text] [Related]
40. In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
Kinnamon KE; Steck EA; Hanson WL; Chapman WL
J Med Chem; 1977 Jun; 20(6):741-4. PubMed ID: 69024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
